β受体阻滞剂与主动脉瓣置换术后临床结局:SWEDEHEART登记报告
基于瑞典SWEDEHEART登记库2006–2020年因主动脉瓣狭窄行孤立SAVR且术后6个月存活的患者,共纳入11 849例,中位随访5.4年。调整年龄、性别和基线合并症后,继续使用β受体阻滞剂与MACE风险升高相关(aHR 1.14,95%CI 1.05–1.23);但敏感性分析纳入时间更新的合并症数据后差异减弱(HR 1.04,95%CI 0.95–1.14,P=0.33)。结论认为β受体阻滞剂并未显示与SAVR后远期不良结局相关,MACE可能更多与潜在心脏病有关。
要点
- 孤立SAVR术后6个月存活患者中,基线79.7%使用β受体阻滞剂,5年后降至62.2%。
- 调整基线合并症后,继续用药与MACE风险升高相关(aHR 1.14,95%CI 1.05–1.23)。
- 敏感性分析纳入时间更新合并症后差异减弱(HR 1.04,95%CI 0.95–1.14,P=0.33),提示混杂影响。
核心结论
- β受体阻滞剂治疗未显示与SAVR后远期不良结局相关,调整新发合并症后差异减弱。
- MACE可能更多与潜在心脏疾病相关,而非β受体阻滞剂治疗本身。
研究设计与样本
- 基于瑞典SWEDEHEART登记库的回顾性队列研究,纳入2006–2020年因主动脉瓣狭窄行孤立SAVR且术后6个月存活的患者。
- 共纳入11 849例,中位随访5.4年(范围0–13.5年),记录与3个其他强制性国家登记库合并。
- 采用Cox比例风险模型分析,药物数据时间更新,调整年龄、性别和基线合并症。
主要发现
- 基线时79.7%患者处方β受体阻滞剂,5年后降至62.2%。
- 继续治疗与MACE风险升高相关(aHR 1.14,95%CI 1.05–1.23)。
- 按年龄、性别和合并症分亚组关联一致,但心房颤动亚组除外(HR 1.05,95%CI 0.93–1.19)。
- 敏感性分析纳入时间更新合并症后组间差异减弱(HR 1.04,95%CI 0.95–1.14,P=0.33)。
临床怎么用
- SAVR术后使用β受体阻滞剂时,应关注并处理新发合并症,而非仅因MACE风险升高而停药。
- 对合并心房颤动的SAVR患者,β受体阻滞剂与MACE的关联不明显(HR 1.05,95%CI 0.93–1.19)。
局限性
- 原文摘要未明确报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Previous reports suggest that betablockers appear non-beneficial after surgical aortic valve replacement (SAVR). This study aims to clarify the associations between betablockers and long-term outcome after SAVR. METHODS: All patients with isolated SAVR due to aortic stenosis in Sweden between 2006 and 2020, alive at 6 months after surgery, were included. Patients were identified in the SWEDEHEART registry, and records were merged with data from 3 other mandatory national registries. Association between dispensed betablockers and major adverse cardiovascular events (MACE) (all-cause mortality, myocardial infarction and stroke) was analyzed using Cox proportional hazards models, with time-updated data on medication and adjusted for age, sex and comorbidities at baseline. RESULTS: In total, 11 849 patients were included [median follow-up 5.4 years (range 0-13.5)]. Betablockers were prescribed to 79.7% of patients at baseline, decreasing to 62.2% after 5 years. Continuing treatment was associated with higher risk of MACE [adjusted hazard ratio 1.14 (95% confidence interval, CI 1.05-1.23)]. The association was consistent over subgroups based on age, sex and comorbidities except atrial fibrillation [hazard ratio (HR) 1.05 (95% CI 0.93-1.19)]. A sensitivity analysis including time-updated data on comorbidites attenuated the difference between the groups [HR 1.04 (95% CI 0.95-1.14, P = 0.33)]. CONCLUSIONS: Treatment with betablockers did not appear to be associated with inferior long-term outcome after SAVR, when adjusting for new concomitant diseases. Thus, it is likely that it is the underlying cardiac diseases that are associated with MACE rather than betablocker treatment.
引用
- Hansson EC, Martinsson A, Baranowska J, et al. Betablockers and clinical outcome after surgical aortic valve replacement: a report from the SWEDEHEART registry. Eur J Cardiothorac Surg. 2024. PMID: 39374543. doi:10.1093/ejcts/ezae365
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。